NCT05495828View on ClinicalTrials.gov

Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

RecruitingOBSERVATIONAL

Enrollment

30

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

December 10, 2024

Study Completion Date

March 10, 2025

Conditions

B-cell Lymphoma

Interventions

DRUG

Orelabrutinib

Orelabrutinib, 150mg, po, qd

Trial Locations (1)

100044

RECRUITING

Deparment of Hematology, Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Peking University People's Hospital

OTHER